Skip to content
Open access

223. Multidomain behavioural profiling in the Flinders Sensitive Line rat and response to escitalopram or a novel butyrylcholinesterase inhibitor: focus on anhedonia

Sep 2026 · International Journal of Neuropsychopharmacology · Vol 29, pp. i110 - i110 · 0 citations

TL;DR

The comparable efficacy of ESC and BChEI in reversing CPP deficits highlights the therapeutic responsiveness of consummatory anhedonia, strengthening the translational validity of the FSL model and position the BChE-ghrelin-dopamine pathway as a promising avenue for further mechanistic exploration in MDD research.

Abstract

Abstract Background Anhedonia is a core symptom of major depressive disorder (MDD) but is challenging to model and to treat. First-line serotonergic antidepressants, e.g., escitalopram (ESC), often show limited efficacy in certain reward-related domains. Anhedonia is multi-dimensional, encompassing motivational drive, consummatory pleasure, and reward learning, yet many preclinical studies assess only consummatory sucrose intake, potentially overlooking critical deficits. The Flinders Sensitive Line (FSL) rat is a validated model of MDD. However, inconsistent findings regarding anhedonia raise questions about whether this model emphasises unique reward-related subdomains. Moreover, anhedonia represents a valuable target for novel antidepressant testing, where the FSL rat may be a valuable translational model. Regulation of reward signalling by butyrylcholinesterase (BChE) via control of bioactive ghrelin represents a novel mechanism influencing these processes. Selective BChE inhibition improves several MDD-relevant behavioural domains in FSL rats through ghrelinergic and dopaminergic pathways, suggesting a reward-specific approach to treating MDD. Considering the multi-dimensional presentation of anhedonia, we investigated whether a typical serotonergic antidepressant like ESC or a novel selective BChE inhibitor (BChEI) would display broad antidepressant-like activity in FSL rats using multidomain behavioural assessment, thus in line with the Research Domain Criteria. Aims & Objectives Define the depressive-like phenotype of the FSL rat, viz., cognitive, anhedonia- and despair-like traits, versus control Flinders Resistant Line (FRL) rats. Assess whether chronic ESC or BChEI treatment can alleviate depressive and anhedonia-like behaviour in FSL rats. Method To establish validity for MDD, FSL rats were subjected to the forced swim test (FST) and novel object recognition test (NORT) as reference behavioural assessments for despair and cognition, respectively. Anhedonia was evaluated across two domains, viz., consummatory reward (sucrose preference test; SPT) and motivational reward learning (conditioned place preference; CPP). Thereafter, behavioural response following chronic ESC (20 mg/kg po x 16 days) or BChEI (30 mg/kg po x 16 days) treatment in FSL rats was assessed. Statistical evaluation included strain comparisons by independent t-tests, with treatment effects analysed using one- or two-way ANOVAs with Bonferroni corrections. Statistical significance was accepted at p < 0.05. Results Vehicle-treated FSL rats demonstrated significantly impaired cognition (NORT) and increased despair (FST) relative to control FRL rats, both reversed by ESC and BChEI. While consummatory reward (SPT) remained intact, FSL rats exhibited a marked deficit in motivational reward learning (CPP), supporting a specific impairment in reward acquisition. Chronic ESC and BChEI treatment produced comparable improvements in CPP performance, restoring motivational reward learning akin to FRL controls. Discussion & Conclusions The value of multidomain reward assessment in preclinical antidepressant research is emphasised. While consummatory reward is preserved in FSL versus FRL rats, motivational and learning-based reward processes are significantly impaired. These findings mirror clinically relevant patterns of anhedonia observed in MDD. The comparable efficacy of ESC and BChEI in reversing CPP deficits highlights the therapeutic responsiveness of consummatory anhedonia, strengthening the translational validity of the FSL model. These data also position the BChE-ghrelin-dopamine pathway as a promising avenue for further mechanistic exploration in MDD research.

Read PDF

Similar papers

Open access Oct 2026

Esketamine alleviates the pain-depression dyad: insights from exploratory transcriptomic profiling and Wnt4-associated molecular alterations within the anterior cingulate cortex

Objective The molecular mechanisms driving esketamine (ESK) efficacy in the pain-depression dyad (PDD) remain incompletely understood. This study investigated the effects of a sub-anesthetic ESK regimen on cortical expression profiles and exploratory signaling markers within the anterior cingulate cortex (ACC). Methods...

Qing-Mei Li, Shu-Ming Liu, Hui-Ling Chen et al. · 0 citations
Open access Oct 2026

A randomized, controlled experimental medicine study of the novel Kv7 channel opener azetukalner in individuals with major depressive disorder and anhedonia

Major Depressive Disorder (MDD) is a common and debilitating disease. Kv7 potassium channels are relevant to reward processing and represent a novel target for depression and anhedonia. Azetukalner is a positive allosteric modulator of Kv7 channels. This phase II, randomized, double-blind, placebo-controlled trial as...

R. Fremont, P. Neukam, Usha Govindarajulu et al. · 0 citations
Sep 2026

Targeting the serotonin 1B receptor for the treatment of depression and anxiety

ABSTRACT Introduction Depressive and anxiety disorders impose a substantial public health burden, yet current serotonergic therapies are limited by delayed onset, modest remission rates, and adverse side effects. Here we put forward the serotonin 1B receptor (5-HT1BR) as an important therapeutic target for mood related...

Sixtine Fleury, Katherine M. Nautiyal · 0 citations
Open access Oct 2026

AAV-mediated Modulation of Dorsal Raphe Serotonergic Neurons Recapitulates Fenfluramine Efficacy in a Rat Model of Dravet Syndrome.

Dravet Syndrome (DS) is a catastrophic developmental and epileptic encephalopathy (DEE) primarily caused by SCN1A haploinsufficiency. It is characterized by refractory hyperthermia-induced seizures, neurodevelopmental delay, and an elevated risk of sudden unexpected death in epilepsy (SUDEP) compared to other childhood...

Wei-Xin Qian, Ying-Zi Huang, Yan-Chun Zheng et al. · 0 citations
Open access Oct 2026

Adult motivation deficits produced by early developmental fluoxetine exposure are rescued by nucleus accumbens mu opioid receptor antagonism

Pursuit of reward drives many aspects of daily life and can be altered in several psychiatric disorders including depression. Reward seeking impairments in depression are reportedly poorly managed by the typical frontline therapeutics, selective serotonin reuptake inhibitors (SSRIs), suggesting that serotonergic mechan...

Emily Cambre, Katherine Najor, Kamila Giermakowski Rios et al. · 0 citations
Open access Oct 2026

Beyond Classical Reward Circuits: Dorsal Striatum Proteomic Alterations in an Adolescent Phencyclidine-Induced Mouse Model of Schizophrenia and Nicotine Use

Schizophrenia and nicotine misuse comorbidity frequently emerges during adolescence. Although the dorsal striatum has received less attention than mesolimbic regions in this context, growing evidence supports its involvement in both schizophrenia-related dysfunction and the transition to compulsive drug-seeking. Here,...

T. P. Souza, A. Rodríguez-Vega, A. C. Dutra-Tavares et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.